文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

未发表试验对儿童药物危害证据合成的影响

Unpublished trials affected evidence synthesis substantially when estimating medication harms in children.
PubMed 文献 · J Clin Epidemiol · 2026-04-18

该研究基于截至2023年2月的Cochrane系统评价,评估未发表试验对儿童药物不良事件合并效应的影响。在740项符合条件的Meta分析中,14.9%纳入了未发表试验;剔除后26.4%的Meta分析效应方向改变,28.2%的统计学显著性改变,8.2%的效应量变化超过50%。未发表试验比例越高,影响越大。

要点

  • 未发表试验可显著改变儿童药物危害的合并效应方向与显著性。
  • 小型Meta分析(少于5项研究)受未发表试验影响更明显。
  • 系统评价应全面检索未发表的危害数据。

核心结论

  • 即使少量符合条件的未发表试验也能显著改变合并效应估计,尤其在药物安全性研究中。

研究设计与样本

  • 收集截至2023年2月发表的、评估儿童药物干预与不良事件的Cochrane系统评价及其rm5文件元数据。
  • 共纳入740项符合条件的Meta分析,总结未发表试验的占比,并通过剔除这些试验复现Meta分析效应。
  • 采用逻辑回归检验未发表试验百分比与影响之间的关联,以OR及其95%CI衡量。

主要发现

  • 740项Meta分析中,14.9%纳入了未发表试验。
  • 剔除未发表试验后,26.4%的Meta分析效应方向改变,28.2%的统计学显著性改变,8.2%的效应量变化超过50%。
  • 亚组分析显示,小型Meta分析(少于5项研究 vs 10项及以上)中方向改变比例为42.9% vs 4.8%,显著性改变比例为46.0% vs 4.8%。
  • 未发表试验比例越高影响越大(例如50% vs 20%,显著性:OR=11.5,95%CI:4.7-28.6,P< .001)。

临床怎么用

  • 系统评价应全面检索未发表的试验危害数据,以更准确地估计儿童药物不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To investigate the impact of unpublished trials on the pooled estimates for medication harms. METHODS: Cochrane reviews published up to February 2023 that evaluated drug interventions and adverse events in children were collected, along with the metadata from rm5 files. The prevalence of unpublished trials among the meta-analyses was summarized, and then the meta-analytic effects were replicated by removing these trials. Association between percentage of unpublished trials and the impact were examined via logistic regression, measured by odds ratio (OR) and its 95% confidence interval. RESULTS: Among 740 eligible meta-analyses, 14.9% included unpublished trials. Excluding these trials changed effect direction in 26.4% of meta-analyses, statistical significance in 28.2%, and magnitude by >50% in 8.2%. Subgroup analyses showed that the impact was more pronounced in smaller meta-analyses, regardless of the effect direction (less than five studies vs those with 10 or more studies: 42.9% vs 4.8%) or the statistical significance (46.0% vs 4.8%). Higher percentage of unpublished trials showed larger impact, regardless of the direction or significance (eg, 50% vs 20%, significance: odds ratio = 11.5, 95% confidence interval: 4.7-28.6, P< .001). CONCLUSION: Even a small number of eligible unpublished trials can substantially alter pooled effect estimates, particularly in drug safety research. Systematic reviews should include a comprehensive search for unpublished harms data from trials.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Yisha Z, Fan Z, Furuya-Kanamori L, et al. Unpublished trials affected evidence synthesis substantially when estimating medication harms in children. J Clin Epidemiol. 2026. PMID: 42009146. doi:10.1016/j.jclinepi.2026.112276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。